• Ferrostatin-1 (Fer-1): Redefining Ferroptosis Assays in Canc

  2026-06-25

  Explore how Ferrostatin-1 (Fer-1) is transforming ferroptosis assay design and oxidative lipid damage inhibition in cancer biology and neurodegenerative disease models. This article offers a unique, in-depth analysis of Fer-1’s mechanistic role, protocol optimization, and the impact of emergent ROS-based therapies.

• Decitabine: Mechanistic Insights and Translational Strategy

  2026-06-25

  This article unpacks the mechanistic underpinnings and translational applications of Decitabine (5-Aza-2'-deoxycytidine), with a focus on bridging bench science and clinical innovation. Beyond its established DNA methyltransferase inhibition, we examine its immunomodulatory impact, protocol integration, and competitive context for cancer epigenetics and immune tolerance restoration. Strategic guidance is provided for translational researchers seeking to maximize the potential of Decitabine in hematopoietic malignancy and solid tumor research.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-06-24

  Schwartz’s dissertation introduces a quantitative distinction between relative and fractional viability in in vitro cancer drug assays, revealing fundamental differences in how proliferation and cell death contribute to drug responses. This approach offers a more nuanced framework for interpreting anticancer compound efficacy, with direct implications for assay design and translational relevance.

• LNP-mRNA Vaccine Encoding C. psittaci MOMP Elicits Protectio

  2026-06-23

  Wang et al. developed a lipid nanoparticle (LNP)-delivered mRNA vaccine encoding the major outer membrane protein (MOMP) of Chlamydia psittaci, demonstrating robust immunogenicity and significant reduction of pathogen burden in BALB/c mice. This study highlights the translational value of mRNA vaccine platforms against zoonotic respiratory pathogens and provides a methodological reference for designing immune-evasive, highly expressible mRNA vaccines.

• Optimizing PDAC Research: Scenario-Driven Insights with VE-8

  2026-06-23

  This article addresses key experimental challenges in cancer research workflows, highlighting how VE-822 (SKU B1383) streamlines DNA damage response inhibition and enhances reproducibility in pancreatic ductal adenocarcinoma (PDAC) assays. Scenario-based Q&As guide researchers through protocol optimization, vendor selection, and data interpretation, with direct links to validated protocols and the APExBIO product resource.

• RITA (NSC 652287) in Cancer Biology: Workflows and Optimizat

  2026-06-22

  RITA (NSC 652287) stands out as a robust MDM2-p53 interaction inhibitor, enabling selective p53 pathway activation in both in vitro and in vivo cancer models. This article delivers actionable protocols, troubleshooting tips, and data-driven insights for maximizing RITA's translational impact in apoptosis assays and tumor xenograft research.

• DiscoveryProbe Natural Product Library Plus: Accelerating An

  2026-06-22

  The DiscoveryProbe Natural Product Library Plus streamlines high-throughput screening for novel antiparasitic leads, offering unparalleled compound diversity and workflow compatibility. By leveraging validated, cell-permeable bioactive compounds, researchers can rapidly pinpoint inhibitors and activators for targets like Cryptosporidium parvum’s AdhE, translating bench insights into therapeutic breakthroughs.

• ML385 and NRF2 Inhibition: New Frontiers in Ferroptosis & AL

  2026-06-21

  Explore how ML385, a selective NRF2 inhibitor, is transforming research on oxidative stress, ferroptosis, and therapeutic resistance. This article uniquely bridges cancer biology and liver disease, highlighting novel assay insights from recent studies.

• SP2509 and the Next Frontier in AML Epigenetic Modulation

  2026-06-20

  Explore how SP2509, a selective LSD1 antagonist from APExBIO, is reshaping translational acute myeloid leukemia (AML) research. This thought-leadership article blends mechanistic insights with actionable strategies, situating SP2509 within the evolving landscape of cancer epigenetics and highlighting its impact on apoptosis induction, differentiation, and the promise of combinatorial therapies.

• Quercetin Suppresses NLRP3 Inflammasome in LPS-Induced Depre

  2026-06-19

  This study demonstrates that quercetin alleviates depressive-like behaviors and cognitive impairment in an LPS-induced mouse model by inhibiting the NLRP3 inflammasome and reducing neuroinflammatory cytokines. The findings provide mechanistic insight into quercetin’s neuroprotective and antidepressant-like effects, supporting its emerging role in translational research for depression-related neuroinflammation.

• ABT-263 (Navitoclax): Precision Apoptosis in PDX Cancer Mode

  2026-06-19

  Explore how ABT-263 (Navitoclax) enables high-fidelity apoptosis research in patient-derived xenograft models, with a focus on assay design and overcoming chemoresistance. This article offers a unique, practical guide for leveraging ABT-263 in advanced cancer biology applications.

• Myriocin: Advanced Insights into Sphingolipid Metabolism and

  2026-06-18

  Explore how Myriocin, a potent serine palmitoyltransferase inhibitor, is transforming sphingolipid metabolism research and elucidating new mechanisms in cell cycle regulation and cardiac remodeling. This article provides a unique, evidence-driven perspective linking molecular action to translational potential.

• SMYD2 Inhibition Mitigates Cisplatin-Induced Renal Fibrosis

  2026-06-18

  This study demonstrates that pharmacological inhibition of SMYD2, using the small molecule AZ505, protects against cisplatin-induced renal fibrosis and inflammation in preclinical models. The findings highlight SMYD2 as a critical epigenetic regulator in chronic kidney disease and provide mechanistic insight into its role in fibrogenic and inflammatory signaling.

• Pifithrin-α (PFTα): Reliable p53 Inhibition in Cell Assays

  2026-06-17

  This article provides scenario-driven, evidence-based guidance on using Pifithrin-α (PFTα, SKU A4206) to overcome common laboratory challenges in p53-dependent apoptosis and ferroptosis assays. It synthesizes current literature and real-world workflow considerations, offering actionable protocols, troubleshooting, and candid vendor recommendations for biomedical researchers.

• Enhancing Assay Precision with CCT007093: PPM1D Inhibitor In

  2026-06-17

  This article provides an evidence-based, scenario-driven discussion of CCT007093 (SKU B3274) as a selective PPM1D inhibitor for dissecting the PPM1D signaling pathway and P38 MAPK activation. Addressing real laboratory challenges, it demonstrates how this DMSO-soluble inhibitor from APExBIO advances reproducibility and data clarity in cancer and acute kidney injury research.

16846 records 1/1124 page Next 12345 下5页 Last page